ENKAM to develop FGL for chronic stress

Copenhagen, Denmark-based ENKAM Pharmaceuticals has reported new study data which show that administration of FGL, a neural cell adhesion molecule mimicking peptide, can prevent the cognitive deficit seen after chronic stress.

According to the firm, the data, which has been accepted for publication in Behavioural Pharmacology, adds to the commercial potential of its new approach for the treatment of Alzheimer's disease. FGL works by protecting neuronal cells. Its activity re-establishes the cognitive function of cells by promoting the connectivity between them and stimulating the formation of new neurons (nerve stem cells). The study also indicates that FGL could have broader therapeutic applications including its use as an anti-depressant.